Quince Therapeutics, Inc. current report, 20 July 2022

Abrir documento

Business Context and Reporting Period

This Form 8-K is a current report filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on July 20, 2022. The filing discloses the departure of an executive officer and the terms of the associated separation agreement.

Key Financial Metrics

The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed relates to the severance package for the departing executive:

  • Severance Payment: $339,000 (cash, lump sum).
  • Severance Basis: Equivalent to nine months of the executive's 2022 base salary.
  • Additional Benefits: Health care continuation and an extended post-termination exercise period for vested stock options.

Material Changes

The primary material change reported is the resignation of Leslie Holsinger, Ph.D., Executive Vice President of Research and Development, effective July 31, 2022. The company entered into a transition agreement to facilitate the handover of activities through the end of the year.

Outlook, Risks, and Contingencies

Change in Control Contingency: If the company consummates a change in control within three months of the departure date, Dr. Holsinger is entitled to:

  • Additional cash severance and COBRA coverage.
  • Payment of the target annual bonus.
  • Accelerated vesting of equity awards.

Management Commentary: The company anticipates entering into a consulting agreement with Dr. Holsinger to ensure a smooth transition of research and development activities.

Investor Verification Checklist

  • Verify the exact terms of the Separation Agreement in the upcoming Form 10-Q for the quarter ended June 30, 2022.
  • Monitor for any announcements regarding a change in control within the next three months, which would trigger additional compensation costs.
  • Confirm the appointment of a successor for the Executive Vice President of Research and Development role.
  • Note that the filing metadata referenced "Quince Therapeutics," but the document content explicitly identifies the registrant as "Cortexyme, Inc."